Lixte Biotechnology Holdings Inc (LIXT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Lixte Biotechnology Holdings Inc (LIXT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10039
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Lixte Biotechnology Holdings Inc (Lixte) is a clinical stage pharmaceutical company, which focuses on the discovery of novel drugs for the treatment of cancer and non-malignant diseases. It develops comprises two classes of drugs, namely, protein phosphatase inhibitors (PTase-i) designated as the LB-100 series; and histone deacetylase inhibitors (HDACi), designated as the LB-200 series of compounds. The company’s product pipeline comprises drug candidates for the treatment of cancer and neurodegenerative disorders such as solid tumors, acute ischemia and Gaucher’s disease, among others. Its lead compound, LB-100 is being developed in Phase I clinical trials. Lixte established a cooperative research and development agreement with National Institute of Neurological Disorders and Stroke of the National Institutes of Health for development of its anti-cancer treatments. Lixte is headquartered in New York, the US.

Lixte Biotechnology Holdings Inc (LIXT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Lixte Biotech Enters into R&D Agreement with the National Cancer Institute 10
Lixte Biotech Enters into R&D Agreement with National Institute of Neurological Disorders and Stroke 11
Equity Offering 12
Lixte Biotech Raises USD1.5 Million in Public Offering of Shares 12
Lixte Biotech Raises USD1 Million in Private Placement of Shares 13
Lixte Biotechnology Raises USD1.8 Million in Private Placement of Preferred Stock 14
Lixte Biotech Raises USD1.8 Million in Private Placement of Series A Convertible Preferred Stock 15
Lixte Biotech Raises USD1.8 Million in Private Placement of Shares 16
Lixte Biotechnology Holdings Inc – Key Competitors 17
Lixte Biotechnology Holdings Inc – Key Employees 18
Lixte Biotechnology Holdings Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
Aug 08, 2018: Yun Yen, MD, PhD and Winson (Sze Chun) Ho, MD join Lixte Biotechnology’s board of directors 20
Clinical Trials 21
Jan 04, 2017: First-In-Human Assessment of LB-100, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lixte Biotechnology Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lixte Biotech Enters into R&D Agreement with the National Cancer Institute 10
Lixte Biotech Enters into R&D Agreement with National Institute of Neurological Disorders and Stroke 11
Lixte Biotech Raises USD1.5 Million in Public Offering of Shares 12
Lixte Biotech Raises USD1 Million in Private Placement of Shares 13
Lixte Biotechnology Raises USD1.8 Million in Private Placement of Preferred Stock 14
Lixte Biotech Raises USD1.8 Million in Private Placement of Series A Convertible Preferred Stock 15
Lixte Biotech Raises USD1.8 Million in Private Placement of Shares 16
Lixte Biotechnology Holdings Inc, Key Competitors 17
Lixte Biotechnology Holdings Inc, Key Employees 18

List of Figures
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Lixte Biotechnology Holdings Inc (LIXT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bitauto Holdings Limited:企業のM&A・事業提携・投資動向
    Bitauto Holdings Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bitauto Holdings Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Global Partners LP (GLP)-石油・ガス分野:企業M&A・提携分析
    Summary Global Partners LP (Global Partners) is a midstream logistics and marketing company. It carries out purchasing, selling and logistics of transporting domestic and Canadian crude oil and other products by rail across its virtual pipeline from the mid-continent region of the US and Canada to t …
  • Cambridge Cognition Holdings Plc (COG):医療機器:M&Aディール及び事業提携情報
    Summary Cambridge Cognition Holdings Plc (Cambridge Cognition) is a neuroscience digital health company. The company offers drug development, digital health technology and cognitive research. Its drug development service include enrich clinical trial recruitment, develop safe and effective treatment …
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development-製薬・医療分野:企業M&A・提携分析
    Summary Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a subsidiary of National Institutes of Health is a research institute that conducts and supports laboratory research, clinical trials, and epidemiological studies. The institute conducts research in the …
  • Hotel Grand Central Limited:企業の戦略・SWOT・財務情報
    Hotel Grand Central Limited - Strategy, SWOT and Corporate Finance Report Summary Hotel Grand Central Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Tesaro Inc (TSRO)-製薬・医療分野:企業M&A・提携分析
    Summary Tesaro Inc (Tesaro) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates, comprising rolapitant, niraparib, and the product candidates under its immuno-oncology platform. VARUBI, the company’s first commercial product is …
  • Maruti Suzuki India Ltd (MARUTI):企業の財務・戦略的SWOT分析
    Maruti Suzuki India Ltd (MARUTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • PT Sinar Mas Agro Resources and Technology Tbk (SMAR):企業の財務・戦略的SWOT分析
    PT Sinar Mas Agro Resources and Technology Tbk (SMAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …
  • Vectura Group Plc (VEC):製薬・医療:M&Aディール及び事業提携情報
    Summary Vectura Group Plc (Vectura) is a formulation and device business for inhaled airways products providing an integrated inhaled drug delivery platform. It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD) …
  • Interprotein Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Interprotein Corp (Interprotein) is a drug development company that develops active modulators for protein-protein interaction (PPI) targets. The company offers products such as IL-6 inhibitor, IgE inhibitor, notch1 inhibitor, tubulin polymerization inhibitors, TIM-3 inhibitor, NKG2A, HLA-E …
  • Pinnacle Entertainment Inc:企業のM&A・事業提携・投資動向
    Pinnacle Entertainment Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pinnacle Entertainment Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • FGL Sports Ltd.:企業の戦略・SWOT・財務情報
    FGL Sports Ltd. - Strategy, SWOT and Corporate Finance Report Summary FGL Sports Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Ameresco Inc (AMRC):企業の財務・戦略的SWOT分析
    Ameresco Inc (AMRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Meridian Bioscience Inc (VIVO):企業の財務・戦略的SWOT分析
    Meridian Bioscience Inc (VIVO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Siemens AG:企業のM&A・事業提携・投資動向
    Siemens AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Siemens AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Amneal Pharmaceuticals Inc (AMRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Amneal Pharmaceuticals Inc (Amneal) formerly Amneal Pharmaceuticals LLC, is an integrated specialty pharmaceutical company that produces generic, specialty and biosimilar medicines. Its product portfolio includes generic and specialty drugs in the therapeutic areas of analgesic, antibiotic, …
  • ObsEva SA (OBSV):企業の財務・戦略的SWOT分析
    ObsEva SA (OBSV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Raia Drogasil SA:企業の戦略・SWOT・財務分析
    Raia Drogasil SA - Strategy, SWOT and Corporate Finance Report Summary Raia Drogasil SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Amerisafe, Inc.:企業の戦略・SWOT・財務情報
    Amerisafe, Inc. - Strategy, SWOT and Corporate Finance Report Summary Amerisafe, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • The Boston Beer Company, Inc.:企業の戦略・SWOT・財務分析
    The Boston Beer Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Boston Beer Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆